ArticleFrontiers in microbiology2020
Retrospective Screening and Analysis of
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Computational Genomics for Resistome Characterization: Current Advancements and Future Challenges Under a One Health Perspective.Antibiotics (Basel, Switzerland) · 2026Review
- A One Health Approach Reveals Farms as Hotspots for Co-Occurrence ofInfection and drug resistance · 2026Article
- Whole-genome analysis of multidrug-resistantJournal of veterinary science · 2025Article
- Investigation of colistin heteroresistance in multidrug-resistantNew microbes and new infections · 2025Article
- When the Last Line Fails: Characterization of Colistin-ResistantPathogens (Basel, Switzerland) · 2025Article
- Metallo Beta Lactamase Enzymes.Indian journal of microbiology · 2025Review
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Risk factors and molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Fujian, China from 2021 to 2023.BMC microbiology · 2024Article
- Colistin: Lights and Shadows of an Older Antibiotic.Molecules (Basel, Switzerland) · 2024Review
- Status and analysis of undetected plague cases in Yunnan Province, China.Frontiers in public health · 2024Article
- Molecular eidemiology of carbapenem-resistant Enterobacter cloacae complex in a tertiary hospital in Shandong, China.BMC microbiology · 2023Article
- Mobile Colistin Resistance (Antibiotics (Basel, Switzerland) · 2023Review
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Comparative genomics and molecular epidemiology of colistin-resistantComputational and structural biotechnology journal · 2023Article
- More thanFrontiers in cellular and infection microbiology · 2023Article
- Article
- Low Level of Colistin Resistance andAntibiotics (Basel, Switzerland) · 2022Article
- An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli.Frontiers in cellular and infection microbiology · 2022Review
- Multiresistant Gram-Negative Pathogens—A Zoonotic Problem.Deutsches Arzteblatt international · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, Gram-negative bacteria have developed multidrug and broad-spectrum drug resistance, and the numbers of species and strains carrying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.